Bluebird Lays Some New Eggs, But They'll Take Time To Hatch
Management outlined four new oncology and one rare disease program during an analyst day. CEO Nick Leschly also talked to Scrip about staying focused on R&D as other gene therapy players get bought out.
You may also be interested in...
A BLA filing for Zynteglo in beta-thalassemia is expected in the second half of 2020 instead of the first half, but the first commercial patient in the EU will be treated in the first half of this year.
UnitedHealthcare’s pharmacy benefit manager highlights potential cost pressures from upcoming novel or improved treatments for diabetes, wet AMD, HIV and migraine, as well as luspatercept for beta thalassemia, in its latest pipeline report.
CEO Nick Leschly talked to Scrip about the European payment strategy for the one-time gene therapy, which will cost €1.575m over five years if treatment is successful.